Progress of immunotherapy for multiple myeloma
10.3760/cma.j.cn115356-20210111-00011
- VernacularTitle:多发性骨髓瘤免疫治疗进展
- Author:
Quande LIN
;
Delong LIU
;
Yongping SONG
- From:
Journal of Leukemia & Lymphoma
2021;30(1):5-10
- CountryChina
- Language:Chinese
-
Abstract:
The clinical application of biological immunotherapy such as chimeric antigen receptor T cells (CAR-T) and novel targeted therapy has explored a new therapy for multiple myeloma (MM) treatment. Targeting B-cell maturation antigen (BCMA), allogeneic CAR-T, antibody-drug conjugate (ADC) and bispecific antibody targeting BCMA have achieved remarkable efficacy and safety in many clinical studies. This article introduces the latest immunotherapy for MM at the 62nd American Society of Hematology (ASH) Annual Meeting.
